Table 3.
Pharmacogenetics of Sulfasalazine (SASP) in Rheumatoid Arthritis (RA)
| Gene Symbol | Polymorphism | Effect of Polymorphism | Pharmacogenetics | References |
|---|---|---|---|---|
| NAT2 | NAT2*4 | Increased activity of NAT2 enzyme | Decreased concentrations of SASP intermediates | [75] |
| (wildtype) | (fast acetylator status) | Less prone to toxicities from SASP | ||
| NAT2*5A | Decreased activity of NAT2 enzyme | Increased concentrations of SASP intermediates | [76, 77] | |
| T341C,C481T | (slow acetylator status) | More prone to toxicities from SASP | ||
| NAT2*5B | Decreased activity of NAT2 enzyme | Increased concentrations of SASP intermediates | [76, 77] | |
| T341C,C481T,A803G | (slow acetylator status) | More prone to toxicities from SASP | ||
| NAT2*5C | Decreased activity of NAT2 enzyme | Increased concentrations of SASP intermediates | [76, 77] | |
| T341C,A803G | (slow acetylator status) | More prone to toxicities from SASP | ||
| NAT2*6 | Decreased activity of NAT2 enzyme | Increased concentrations of SASP intermediates | [76, 77] | |
| C282T,G590A | (slow acetylator status) | More prone to toxicities from SASP | ||
| NAT2*7 | Decreased activity of NAT2 enzyme | Increased concentrations of SASP intermediates | [76, 77] | |
| C282T,G857A | (slow acetylator status) | More prone to toxicities from SASP |
NAT2 = N-acetyltransferase 2.